![4-{[3′,4′-(Methylenedioxy)benzyl]amino}-6-methoxyquinazoline (CAS 150450-42-3) - chemical structure image](https://media.scbt.com/product/4-3prime-4prime-methylenedioxybenzylamino-6-methoxyquinazoline-150450-42-3-structure_25_66_b_256627.jpg)
![4-{[3′,4′-(Methylenedioxy)benzyl]amino}-6-methoxyquinazoline (CAS 150450-42-3) - chemical structure image](https://media.scbt.com/product/4-3prime-4prime-methylenedioxybenzylamino-6-methoxyquinazoline-150450-42-3-structure_25_66_t_256627.jpg "Molecular structure of 4-{[3′,4′-(Methylenedioxy)benzyl]amino}-6-methoxyquinazoline, CAS Number: 150450-42-3")
Molecular structure of 4-{[3′,4′-(Methylenedioxy)benzyl]amino}-6-methoxyquinazoline, CAS Number: 150450-42-3
4-{[3′,4′-(Methylenedioxy)benzyl]amino}-6-methoxyquinazoline (CAS 150450-42-3)
Alternate Names:
N-(1,3-benzodioxol-5-ylmethyl)-6-methoxy-4-quinazolinamine
Application:
4-{[3′,4′-(Methylenedioxy)benzyl]amino}-6-methoxyquinazoline is an inhibitor of cGMP-specific phosphodiesterase
CAS Number:
150450-42-3
Molecular Weight:
309.3
Molecular Formula:
C17H15N3O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
4-{[3′,4′-(Methylenedioxy)benzyl]amino}-6-methoxyquinazoline has been demonstrated to be a specific and potent inhibitor of cGMP-specific phosphodiesterase. Additionally, it has also been shown in isolated porcine coronary arteries, to elevate the intracellular cGMP level without causing any change in the cAMP level. It is not shown to have an effect on other PDE isozymes.
4-{[3′,4′-(Methylenedioxy)benzyl]amino}-6-methoxyquinazoline (CAS 150450-42-3) References
- Role of cyclic nucleotides in vasodilations of the rat thoracic aorta induced by adenosine analogues. | Hourani, SM., et al. 2001. Br J Pharmacol. 133: 833-40. PMID: 11454656
- Long-term potentiation in hippocampus involves sequential activation of soluble guanylate cyclase, cGMP-dependent protein kinase, and cGMP-degrading phosphodiesterase. | Monfort, P., et al. 2002. J Neurosci. 22: 10116-22. PMID: 12451112
- Increased hydrogen peroxide downregulates soluble guanylate cyclase in the lungs of lambs with persistent pulmonary hypertension of the newborn. | Wedgwood, S., et al. 2005. Am J Physiol Lung Cell Mol Physiol. 289: L660-6. PMID: 15937064
- Phosphorylation of TRPC6 channels at Thr69 is required for anti-hypertrophic effects of phosphodiesterase 5 inhibition. | Nishida, M., et al. 2010. J Biol Chem. 285: 13244-53. PMID: 20177073
- Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model. | Maiga, M., et al. 2012. PLoS One. 7: e30749. PMID: 22319585
- New insights into the dynamic regulation of water and acid-base balance by renal epithelial cells. | Brown, D., et al. 2012. Am J Physiol Cell Physiol. 302: C1421-33. PMID: 22460710
- Phosphodiesterase 5 inhibition ameliorates angiontensin II-induced podocyte dysmotility via the protein kinase G-mediated downregulation of TRPC6 activity. | Hall, G., et al. 2014. Am J Physiol Renal Physiol. 306: F1442-50. PMID: 24740790
- TRPC5-eNOS Axis Negatively Regulates ATP-Induced Cardiomyocyte Hypertrophy. | Sunggip, C., et al. 2018. Front Pharmacol. 9: 523. PMID: 29872396
- Cyclic AMP-hydrolyzing phosphodiesterase inhibitors potentiate statin-induced cancer cell death. | Longo, J., et al. 2020. Mol Oncol. 14: 2533-2545. PMID: 32749766
- Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity. | Takase, Y., et al. 1994. J Med Chem. 37: 2106-11. PMID: 8027992
Inhibitor of:
PDE5A.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
4-{[3',4'-(Methylenedioxy)benzyl]amino}-6-methoxyquinazoline, 1 mg | sc-352371 | 1 mg | $140.00 |